Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393755 · ClinicalTrials.gov registry record · Phase 1
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase 1 study of Rectal Adenocarcinoma and Colon Adenocarcinoma, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT02393755 is a Phase 1 study of Rectal Adenocarcinoma and Colon Adenocarcinoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 42 participants, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02393755, a Phase 1 study of Rectal Adenocarcinoma and Colon Adenocarcinoma, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- OTHER Laboratory Biomarker Analysis
- DRUG Nintedanib
- OTHER Pharmacological Study
Study Locations (2)
California
- City of Hope Comprehensive Cancer Center - Duarte
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-05-08 |
| Est. Completion | 2021-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393755
The ClinicalTrials.gov registry entry for NCT02393755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (66% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT02393755 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT02393755 about?
NCT02393755 is a clinical study titled "Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer". This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic)...
What is the current status of trial NCT02393755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-05-08. Estimated completion is 2021-05-18.
What conditions does trial NCT02393755 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma, Colon Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer.
What interventions are being tested in trial NCT02393755?
The interventions under investigation include: Capecitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Nintedanib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02393755?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393755 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
RECRUITING · Phase 1
-
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
RECRUITING · Phase 1
-
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.